Sphingosine-1-phosphate receptor type 5 (S1P5) agonism: A potential new mechanism for the treatment of neuronopathic features of Niemann-Pick disease type C and neurodegenerative sphingolipidoses

France, Nicholas; Liu, Enchi; Carlisle, Holly; Barlow, Carrolee

doi:10.1016/j.ymgme.2019.11.134

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, a predecessor compound with selectivity similar to ESB1609, A-971432, 19 has been shown to be beneficial in HD and AD mouse models. 17,21 ESB1609 is designed to restore lipid homeostasis in the CNS by promoting cytosolic egress of S1P to elicit the reduction of abnormal levels of ceramide and cholesterol in disease. Because of these effects, ESB1609 agonism of the S1P5 receptor has therapeutic potential across multiple disorders affecting sphingolipid synthesis/metabolism including neuronopathic lysosomal storage and neurodegenerative disorders.…”

Section: Discussionmentioning

confidence: 99%

“…This is the first report of the safety, tolerability, and PK of oral ESB1609, an S1P5 receptor selective agonist, in humans. Previously, a predecessor compound with selectivity similar to ESB1609, A‐971432, 19 has been shown to be beneficial in HD and AD mouse models 17,21 . ESB1609 is designed to restore lipid homeostasis in the CNS by promoting cytosolic egress of S1P to elicit the reduction of abnormal levels of ceramide and cholesterol in disease.…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, A‐971432 19 normalized CNS glycosphingolipids and improved function and survival in a mouse model of NPC 17,21 …”

Section: Figurementioning

confidence: 97%

See 2 more Smart Citations

A Phase 1 First‐in‐Human Single‐Ascending‐Dose Trial With ESB1609, a Selective Agonist to the Sphingosine‐1‐Phosphate Receptor 5

France,

Rubino,

Safir

et al. 2023

Clinical Pharm in Drug Dev

Self Cite

View full text Add to dashboard Cite

ESB1609 is a small‐molecule sphingosine‐1‐phosphate‐5 receptor–selective agonist designed to restore lipid homeostasis by promoting cytosolic egress of sphingosine‐1‐phosphate to reduce abnormal levels of ceramide and cholesterol in disease. A phase 1 study was conducted in healthy volunteers to determine the safety, tolerability, and pharmacokinetics of ESB1609. Following single oral doses, ESB1609 demonstrated linear pharmacokinetics in plasma and cerebrospinal fluid (CSF) for formulations containing sodium laurel sulfate. Plasma and CSF median time to maximum drug concentration (tmax) were reached by 4–5 hours and 6–10 hours, respectively. The delay in achieving tmax in CSF relative to plasma, likely due to the high protein binding of ESB1609, was also observed in 2 rat studies. Continuous CSF collection via indwelling catheters confirmed that a highly protein‐bound compound is measurable and established the kinetics of ESB1609 in human CSF. Mean plasma terminal elimination half‐lives ranged from 20.2 to 26.8 hours. The effect of either a high‐fat or standard meal increased maximum plasma concentration and area under the concentration‐time curve from time 0 to infinity compared to the fasted state by 2.42–4.34‐fold higher, but tmax and half‐life remained the same irrespective of fed state. ESB1609 crosses the blood‐brain barrier with CSF:plasma ratios ranging between 0.04% and 0.07% across dose levels. ESB1609 demonstrated a favorable safety and tolerability profile at exposures expected to be efficacious.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%